GALDERMA GROUP AG Total Liabilities
GALDERMA GROUP AG total liabilities. Based on the latest financial reports, GALDERMA GROUP AG (GALDY) has total liabilities worth $5.24 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See GALDERMA GROUP AG (GALDY) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of GALDERMA GROUP AG (2023–2025)
Total liabilities of GALDERMA GROUP AG from 2023 to 2025. This chart illustrates how GALDERMA GROUP AG's total liabilities have evolved over time, based on quarterly financial data.
GALDERMA GROUP AG Competitors by Total Liabilities
The table below lists competitors of GALDERMA GROUP AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thales S.A.
PA:HO
|
France | €31.72 Billion |
|
ASE Industrial Holding Co Ltd ADR
NYSE:ASX
|
USA | $515.97 Billion |
|
Electronic Arts Inc
NASDAQ:EA
|
USA | $6.37 Billion |
|
NAURA Technology Group Co Ltd
SHE:002371
|
China | CN¥45.54 Billion |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
Germany | €262.65 Billion |
|
Discover Financial Services
NYSE:DFS
|
USA | $128.95 Billion |
|
MetLife Inc
NYSE:MET
|
USA | $715.41 Billion |
|
NATWEST GROUP SP.ADR/2
F:RYS
|
Germany | €705.97 Billion |
Liability Composition Analysis (2023–2025)
This chart breaks down GALDERMA GROUP AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of GALDERMA GROUP AG.
Liquidity & Leverage Metrics
GALDERMA GROUP AG Total Liabilities Ratios Explained
GALDERMA GROUP AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GALDERMA GROUP AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GALDERMA GROUP AG (2023–2025)
The table below shows the annual total liabilities of GALDERMA GROUP AG from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.24 Billion | +8.64% |
| 2024-12-31 | $4.83 Billion | -32.03% |
| 2023-12-31 | $7.10 Billion | -- |
About GALDERMA GROUP AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more